Galápagos

Regulated information 12 May 2011

Galapagos receives transparency notifications

Mechelen, Belgium; 12 May 2011 – Galapagos NV (Euronext: GLPG) announced today that it has received transparency notifications pursuant to the Belgian transparency legislation (Belgian Act of 2 May 2007) concerning major holdings in Belgian listed companies from Aviva plc and Delta Lloyd NV.

Galapagos received transparency notifications on 9 May 2011 from Aviva and from Delta Lloyd and its subsidiary Delta Lloyd Asset Management NV. The direct participation in Galapagos is held by Delta Lloyd Asset Management. Aviva has reduced its stake in Delta Lloyd to 40% and as a result Delta Lloyd and its Group of Companies are no longer considered to be a subsidiary of Aviva. Therefore, the indirect participation of Aviva in Galapagos is reduced to zero shares. Delta Lloyd Asset Management holds 3,000,000 Galapagos shares, which represent 11.36% of the current 26,411,480 outstanding Galapagos shares. This participation represents an increase from the previous 2,485,000 shares notified by Aviva in December 2008.

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing one of the largest pipelines in biotech, with six programs in development and over 50 discovery programs. Through risk/reward-sharing alliances with GlaxoSmithKline, Eli Lilly, Janssen Pharmaceutica, Roche and Servier, Galapagos is eligible to receive up to €2.5 billion in downstream milestones, plus royalties. The Galapagos Group has over 800 employees and operates facilities in seven countries, with global headquarters in Mechelen, Belgium. More info at: www.glpg.com

CONTACT

Galapagos NV
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com